SCHEMBL3125820

SCHEMBL3125820

CCOc1cc(N(Cc2cccc(F)c2)c2cccc(C(=O)O)c2)ccc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
MRGPRX4 Q96LA9 6/20 0.50
PPARA Q07869 2/20 0.46
TSHR P16473 1/20 0.46
MEP1B Q16820 2/20 0.45
NR4A2 P43354 2/20 0.45
LPAR1 Q92633 2/20 0.44
LPAR5 Q9H1C0 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128367 0.93 MRGPRX4 (0.49) KMT2AMRGPRX4PPARAMEP1BNR4A2
SCHEMBL3126453 0.89 MRGPRX4 (0.45) KMT2AMEN1MRGPRX4PPARAMEP1B
SCHEMBL3131007 0.88 KMT2A (0.45) KMT2AMEN1MRGPRX4LPAR1LPAR5
SCHEMBL2905916 0.88 MEP1B (0.48) MRGPRX4PPARAMEP1BNR4A2LPAR1
SCHEMBL3126269 0.86 TSHR (0.48) KMT2AMEN1MRGPRX4PPARATSHR
SCHEMBL3123732 0.85 MRGPRX4 (0.44) KMT2AMRGPRX4PPARAMEP1BNR4A2
SCHEMBL4186765 0.84 GRM2 (0.47) MRGPRX4TSHRL3MBTL1MAPTNPSR1
SCHEMBL3131075 0.84 TSHR (0.46) KMT2AMEN1MRGPRX4PPARATSHR
SCHEMBL3192935 0.84 PDE4A (0.56) KMT2AMRGPRX4PPARAMEP1BLPAR1
SCHEMBL3214547 0.84 PDE4A (0.58) LPAR1LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B KMT2A 1324/4885MEN1 3385/4885MRGPRX4 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.